By Fineline Cube 
MicroTech Medical (Hangzhou) Co., Ltd. (HKG: 2235) announced that its LinX Continuous Glucose Monitoring (CGM) System (international brand name AiDEX X) received marketing approval in India for continuous and dynamic blood glucose monitoring in adults, marking the company’s first major regulatory expansion into the South Asian diabetes market.
Regulatory Milestone
| Item | Detail |
|---|---|
| Product | LinX CGM System (AiDEX X) |
| Company | MicroTech Medical (Hangzhou) Co., Ltd. (2235.HK) |
| Agency | Indian Regulatory Authority (CDSCO) |
| Approval Type | Marketing authorization |
| Indication | Continuous glucose monitoring in adults with diabetes |
| Geography | India (world’s second‑largest diabetes population) |
| Next Step | Commercial launch via distribution partners H1 2026 |
Company & Product Profile
- Founded: 2011 – Focused on diabetes treatment and monitoring devices
- Listed: Hong Kong Stock Exchange (HKEX) on 19 Oct 2021 (2235.HK)
- Technology: LinX CGM offers real‑time, dynamic glucose monitoring with 14‑day sensor wear
- Competitive Edge: Cost‑effective alternative to multinational CGM brands; calibrated for Asian patient physiology
- Global Strategy: Aims to optimize diabetes management in China and emerging markets
Market Context & Outlook
| Metric | Value |
|---|---|
| India Diabetes Population | 77 million diagnosed (2024); 25% use CGM |
| India CGM Market Size | ₹4,200 crore (~US$500 million) |
| Growth CAGR | 22% (2024‑2030) |
| MicroTech Market Share Target | 10‑15% by 2028 |
| Peak Sales Forecast (India) | US$80‑120 million annually by 2029 |
| Pricing Strategy | 30‑40% discount vs. Dexcom and Abbott FreeStyle to capture price‑sensitive segment |
- Distribution: Partnership negotiations with Apollo Hospitals and Fortis Healthcare underway; coverage of 50‑80 tier‑1/2 hospitals by end‑2026
- Reimbursement Path: India’s Ayushman Bharat program may include CGM for Type 1 patients; private insurance coverage expanding
- Manufacturing: Hangzhou facility can supply 2 million sensors/year; dedicated India assembly line planned 2027
Forward‑Looking Statements
This brief contains forward‑looking statements regarding LinX CGM’s commercial launch, market penetration, and revenue projections in India. Actual results may differ materially due to risks including competitive responses, distribution challenges, and regulatory changes.-Fineline Info & Tech